CO6300956A2 - Farmaco antiulcera estable superior en la capacidad de absorcion - Google Patents

Farmaco antiulcera estable superior en la capacidad de absorcion

Info

Publication number
CO6300956A2
CO6300956A2 CO10124417A CO10124417A CO6300956A2 CO 6300956 A2 CO6300956 A2 CO 6300956A2 CO 10124417 A CO10124417 A CO 10124417A CO 10124417 A CO10124417 A CO 10124417A CO 6300956 A2 CO6300956 A2 CO 6300956A2
Authority
CO
Colombia
Prior art keywords
absorption capacity
pharmaco
cell
stable anti
superior stable
Prior art date
Application number
CO10124417A
Other languages
English (en)
Inventor
Hideo Hashimoto
Tadashi Urai
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40577894&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6300956(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of CO6300956A2 publication Critical patent/CO6300956A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se provee un cristal de (R)-2-[[[3-metil-4-(2,2,2- trifluoroetoxi)-2-piridinil]metil]sulfinil]-1H-bencimidazol que muestra un patrón de difracción de rayos X de polvo con picos característicos en espacios interplanos (d) de 10,06±0,2, 8,70±0,2, 6,57±0,2, 5,59±0,2 y 4,00±0,2 Angstroms. La presente invención provee un fármaco antiúlcera estable superior en la capacidad de absorción.
CO10124417A 2008-03-10 2010-10-07 Farmaco antiulcera estable superior en la capacidad de absorcion CO6300956A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2008059342 2008-03-10

Publications (1)

Publication Number Publication Date
CO6300956A2 true CO6300956A2 (es) 2011-07-21

Family

ID=40577894

Family Applications (1)

Application Number Title Priority Date Filing Date
CO10124417A CO6300956A2 (es) 2008-03-10 2010-10-07 Farmaco antiulcera estable superior en la capacidad de absorcion

Country Status (30)

Country Link
US (1) US8222422B2 (es)
EP (1) EP2262790B1 (es)
JP (3) JP2011513202A (es)
KR (1) KR20100123758A (es)
CN (1) CN102026994B (es)
AR (1) AR070972A1 (es)
AU (1) AU2009224247B2 (es)
BR (1) BRPI0909651A2 (es)
CA (1) CA2671369C (es)
CL (1) CL2009000547A1 (es)
CO (1) CO6300956A2 (es)
CR (1) CR11707A (es)
DO (1) DOP2010000274A (es)
EA (1) EA017064B1 (es)
EC (1) ECSP10010531A (es)
ES (1) ES2638463T3 (es)
GE (1) GEP20125649B (es)
IL (1) IL207867A0 (es)
LT (1) LT2262790T (es)
MA (1) MA32215B1 (es)
MX (1) MX2010009641A (es)
MY (1) MY150833A (es)
NZ (1) NZ588379A (es)
PE (1) PE20091680A1 (es)
PT (1) PT2262790T (es)
TW (1) TWI447110B (es)
UA (1) UA103189C2 (es)
UY (1) UY31695A (es)
WO (1) WO2009113696A1 (es)
ZA (1) ZA201006754B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011004387A2 (en) 2009-06-18 2011-01-13 Matrix Laboratories Ltd Process for the preparation of dexlansoprazole polymorphic forms
CN102108077B (zh) * 2009-12-23 2013-09-25 江苏豪森医药集团有限公司 制备右兰索拉唑的方法
CA2788147A1 (en) * 2010-01-29 2011-08-04 Ranbaxy Laboratories Limited Process for the preparation of crystalline forms of dexlansoprazole
CN104447695A (zh) * 2013-11-22 2015-03-25 广东东阳光药业有限公司 一种苯并咪唑化合物的水合物
KR20160144927A (ko) 2015-06-08 2016-12-19 씨제이헬스케어 주식회사 야간 산 분비에 대한 벤즈이미다졸 유도체의 용도
KR102561697B1 (ko) 2016-11-29 2023-07-28 피티씨 테라퓨틱스 엠피, 인크. 세피아프테린의 다형체 및 그의 염
CN106866631A (zh) * 2017-04-06 2017-06-20 山东裕欣药业有限公司 一种右旋兰索拉唑晶型及制备方法
JP2020532535A (ja) 2017-09-01 2020-11-12 ピーティーシー セラピューティクス エムピー，インコーポレイテッド セピアプテリンを含む医薬組成物及びその使用
DK3801526T3 (da) * 2018-05-25 2024-03-25 Cardurion Pharmaceuticals Inc Monohydrate og krystallinske former af 6-[(3s,4s)-4-methyl-1- (pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl- 7h-imidazo[1,5-a]pyrazin-8-on
EP3822249A4 (en) * 2018-07-13 2022-04-13 Kyowa Hakko Bio Co., Ltd. CRYSTAL OF EUCOMIC ACID NONSOLVATE AND METHOD OF PREPARATION THEREOF
CN113376273B (zh) * 2021-06-02 2023-03-17 国药集团精方（安徽）药业股份有限公司 一种清心莲子饮hplc特征图谱的检测方法及该特征图谱的应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6150978A (ja) 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
DK171989B1 (da) 1987-08-04 1997-09-08 Takeda Chemical Industries Ltd Fremgangsmåde til fremstilling af 2-(2-pyridylmethylsulfinyl)-benzimidazoler
DE4035455A1 (de) 1990-11-08 1992-05-14 Byk Gulden Lomberg Chem Fab Enantiomerentrennung
SE504459C2 (sv) 1994-07-15 1997-02-17 Astra Ab Förfarande för framställning av substituerade sulfoxider
GB9423968D0 (en) 1994-11-28 1995-01-11 Astra Ab Resolution
HRP960232A2 (en) 1995-07-03 1998-02-28 Astra Ab A process for the optical purification of compounds
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
TW385306B (en) * 1996-11-14 2000-03-21 Takeda Chemical Industries Ltd Method for producing crystals of benzimidazole derivatives
WO1998022118A1 (en) 1996-11-22 1998-05-28 The Procter & Gamble Company Compositions for the treatment of gastrointestinal disorders containing bismuth and nsaid
SE510666C2 (sv) 1996-12-20 1999-06-14 Astra Ab Nya Kristallmodifikationer
DE59801792D1 (de) * 1997-08-08 2001-11-22 Aventis Pharma Gmbh Kristallform von N-(4-Trifluormethylphenyl)-5-methylisoxazol-4-carbonsäureamid
JP2002501897A (ja) 1998-01-30 2002-01-22 セプラコール， インク． Ｒ−ランソプラゾール組成物及び方法
JP2002501896A (ja) 1998-01-30 2002-01-22 セプラコール， インク． Ｓ−ランソプラゾール組成物及び方法
WO1999056698A2 (en) 1998-05-06 1999-11-11 Københavns Universitet Treatment of celiac disease
JP3283252B2 (ja) * 1999-06-17 2002-05-20 武田薬品工業株式会社 ベンズイミダゾール化合物の結晶
TWI275587B (en) 1999-06-17 2007-03-11 Takeda Chemical Industries Ltd A crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
CA2762960C (en) * 2000-05-15 2014-07-22 Takeda Pharmaceutical Company Limited Recrystallization processes for obtaining anhydrous optically active lansoprazole
JP3374314B2 (ja) * 2000-05-15 2003-02-04 武田薬品工業株式会社 結晶の製造法
JP4327424B2 (ja) * 2000-05-15 2009-09-09 武田薬品工業株式会社 結晶の製造法
KR100887912B1 (ko) * 2000-12-01 2009-03-12 다케다 야쿠힌 고교 가부시키가이샤 (ｒ)- 또는 (ｓ)-란소프라졸의 결정화 방법
JP4160293B2 (ja) * 2000-12-01 2008-10-01 武田薬品工業株式会社 結晶の製造法
JP4749660B2 (ja) * 2002-10-16 2011-08-17 武田薬品工業株式会社 安定な固形製剤
EP1552833B1 (en) 2002-10-16 2016-12-28 Takeda Pharmaceutical Company Limited Process for producing an amorphous optically active isomer of lansoprazole
EP2227462A1 (en) 2007-12-31 2010-09-15 Takeda Pharmaceutical Company Limited Crystalline solvated forms of (r) -2- [[[3-methyl-4- (2, 2, 2-trifluoroethoxy) -2-pyridinyl]methyl]sulfinyl]-1h-benz imidazole

Also Published As

Publication number Publication date
WO2009113696A1 (en) 2009-09-17
EA201071053A1 (ru) 2011-04-29
AR070972A1 (es) 2010-05-19
EA017064B1 (ru) 2012-09-28
EP2262790B1 (en) 2017-06-07
MX2010009641A (es) 2010-09-22
JP2011513202A (ja) 2011-04-28
IL207867A0 (en) 2010-12-30
KR20100123758A (ko) 2010-11-24
UA103189C2 (ru) 2013-09-25
MA32215B1 (fr) 2011-04-01
US8222422B2 (en) 2012-07-17
JP2015163623A (ja) 2015-09-10
JP2014015477A (ja) 2014-01-30
CN102026994B (zh) 2014-05-07
TW200938531A (en) 2009-09-16
AU2009224247B2 (en) 2013-12-12
MY150833A (en) 2014-02-28
AU2009224247A1 (en) 2009-09-17
AU2009224247A2 (en) 2010-10-28
CA2671369C (en) 2011-05-10
TWI447110B (zh) 2014-08-01
ECSP10010531A (es) 2010-11-30
US20110046183A1 (en) 2011-02-24
NZ588379A (en) 2012-07-27
BRPI0909651A2 (pt) 2015-09-22
PT2262790T (pt) 2017-07-18
CR11707A (es) 2010-11-04
ZA201006754B (en) 2011-11-30
ES2638463T3 (es) 2017-10-20
PE20091680A1 (es) 2009-11-16
DOP2010000274A (es) 2010-09-30
CN102026994A (zh) 2011-04-20
CA2671369A1 (en) 2009-09-10
EP2262790A1 (en) 2010-12-22
CL2009000547A1 (es) 2010-05-07
UY31695A (es) 2009-11-10
GEP20125649B (en) 2012-09-25
LT2262790T (lt) 2017-08-25

Similar Documents

Publication Publication Date Title
CO6300956A2 (es) Farmaco antiulcera estable superior en la capacidad de absorcion
EP2292612A3 (en) Crystalline solvated forms of (r)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1h-benzimidazole
TW200738655A (en) Novel bicyclic sulfonamide derivatives
TW200732303A (en) Novel fused pyrrole derivatives
IL177513A0 (en) Fused heterocyclic derivative, medicinal composition containing the same, and medicinal use thereof
WO2004022060A8 (en) (1h-benzoimidazol-2-yl)-(piperazinyl)-methanone derivatives and related compounds as histamine h4-receptor antagonists for the treatment of inflammatory and allergic disorders
TW200833324A (en) Sulfonamide derivatives
ATE372998T1 (de) 1-aminophthalazinderivate, deren herstellung und deren therapeutische verwendung
ATE498618T1 (de) Neue zyklische harnstoffderivate, deren herstellung und pharmazeutische verwendung damit als kinase-inhibitoren
IL190754A0 (en) Fused heterocyclic derivative, medicinal composition containing the same, and medicinal use thereof
MX2009004441A (es) Derivados de indazol utiles como inhibidores de las isoformas de higado.
NO20050883L (no) Ny fremgangsmate for syntesen (IS)-4,5-dimetoksy-1-(metylaminometyl)-benzocyklobutan og addisjonssalter derav, og anvendelse i syntesen av ivabradin og addisjonssalter derav med en farmasoytisk akseptabel syre
NZ579928A (en) Fluorinated derivatives of deferiprone
PL2120864T3 (pl) Kompozycja do podawania składników biologicznie czynnych w okolicy narządów płciowych i odbytnicy, i jej zastosowania
WO2005075450A3 (en) Spiro-benzodioxoles and their use as cb1 antagonists
MX2010002341A (es) Derivados de bencimidazol usados como agonistas del receptor x de farnesoide.
MX2009006315A (es) Compuesto heterociclico fusionado.
NZ598427A (en) Stabilized amorphous forms of imatinib mesylate with cyclodextrin complex
FR2916905B1 (fr) Nouvelle composition pour la fabrication d'electrodes, electrodes et batteries en resultant.
WO2009062874A3 (en) Benzimidazole derivatives and their use as fxr agonists
WO2008045777A3 (en) A process for the preparation of benzimidazole derivatives and their salts
WO2007099171A3 (en) Bicyclo-pyrazoles active as kinase inhibitors
WO2007118151A3 (en) Spirocyclic heterocyclic derivatives and methods of their use
EP2147922A4 (en) CONDENSED HETEROCYCLIC DERIVATIVE, PHARMACEUTICAL COMPOSITION CONTAINING THE DERIVATIVE, AND USE OF THE COMPOSITION FOR MEDICAL PURPOSES
ATE441643T1 (de) N-ä(4,5-diphenylpyrimidin-2- yl)methylüaminderivate, deren herstellung und deren therapeutische verwendung

Legal Events

Date Code Title Description
FC Application refused